RGN1016

RGN1016 is an investigational drug developed by National Taiwan University. It has been described in two different contexts: - As a small molecule drug, it was evaluated in a Phase 1 clinical trial for safety, tolerability, and pharmacokinetics in healthy male subjects. The primary indications explored include cognitive impairment and Alzheimer's disease[2][4]. - There is also mention of RGN1016 as an antibody-drug conjugate (ADC) being developed for cancer treatment; this source describes it as targeting specific antigens on cancer cells to deliver cytotoxic agents directly to tumors[1]. However, the majority of detailed clinical data available pertains to its development as a small molecule for neurological conditions.